Latest news with #LeerinkPartners
Business Insider
3 days ago
- Business
- Business Insider
Leerink Partners Remains a Hold on Quanterix (QTRX)
Leerink Partners analyst Puneet Souda maintained a Hold rating on Quanterix (QTRX – Research Report) on June 2. The company's shares closed yesterday at $5.58. Confident Investing Starts Here: Souda covers the Healthcare sector, focusing on stocks such as Quanterix, Bruker, and Guardant Health. According to TipRanks, Souda has an average return of -12.3% and a 29.46% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Quanterix with a $12.33 average price target. Based on Quanterix's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $30.33 million and a GAAP net loss of $20.5 million. In comparison, last year the company earned a revenue of $32.07 million and had a GAAP net loss of $10.07 million
Business Insider
3 days ago
- Business
- Business Insider
Leerink Partners Sticks to Its Buy Rating for Universal Health (UHS)
In a report released yesterday, Whit Mayo from Leerink Partners maintained a Buy rating on Universal Health (UHS – Research Report), with a price target of $252.00. The company's shares closed yesterday at $188.65. Confident Investing Starts Here: Mayo covers the Healthcare sector, focusing on stocks such as Humana, Pediatrix Medical Group, and Tenet Healthcare. According to TipRanks, Mayo has an average return of 2.9% and a 49.75% success rate on recommended stocks. In addition to Leerink Partners, Universal Health also received a Buy from Wells Fargo's Stephen Baxter in a report issued on May 29. However, yesterday, Morgan Stanley maintained a Hold rating on Universal Health (NYSE: UHS). Based on Universal Health's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.1 billion and a net profit of $316.68 million. In comparison, last year the company earned a revenue of $3.84 billion and had a net profit of $261.83 million Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UHS in relation to earlier this year. Last month, Maria Singer Ruderman, a Director at UHS sold 1,097.00 shares for a total of $210,042.59.
Business Insider
3 days ago
- Business
- Business Insider
Leerink Partners Keeps Their Buy Rating on uniQure (QURE)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on uniQure (QURE – Research Report) on June 3 and set a price target of $48.00. The company's shares closed yesterday at $14.96. Confident Investing Starts Here: Schwartz covers the Healthcare sector, focusing on stocks such as uniQure, KalVista Pharmaceuticals, and Sarepta Therapeutics. According to TipRanks, Schwartz has an average return of 10.5% and a 42.05% success rate on recommended stocks. Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $38.40, implying a 156.68% upside from current levels. In a report released on June 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target. Based on uniQure's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.57 million and a GAAP net loss of $43.64 million. In comparison, last year the company earned a revenue of $8.49 million and had a GAAP net loss of $65.62 million Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year. Most recently, in March 2025, Jeannette Potts, the CLO of QURE sold 7,076.00 shares for a total of $72,812.04.
Business Insider
3 days ago
- Business
- Business Insider
Leerink Partners Remains a Hold on Amgen (AMGN)
In a report released on June 3, David Risinger from Leerink Partners maintained a Hold rating on Amgen (AMGN – Research Report). The company's shares closed yesterday at $287.01. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Johnson & Johnson. According to TipRanks, Risinger has an average return of 8.3% and a 52.15% success rate on recommended stocks. In addition to Leerink Partners, Amgen also received a Hold from Guggenheim's Vamil Divan in a report issued on May 20. However, on June 3, Piper Sandler reiterated a Buy rating on Amgen (NASDAQ: AMGN).
Business Insider
3 days ago
- Business
- Business Insider
Leerink Partners Sticks to Its Buy Rating for HCA Healthcare (HCA)
Leerink Partners analyst Whit Mayo maintained a Buy rating on HCA Healthcare (HCA – Research Report) yesterday and set a price target of $420.00. The company's shares closed yesterday at $381.66. Confident Investing Starts Here: Mayo covers the Healthcare sector, focusing on stocks such as Humana, Pediatrix Medical Group, and Tenet Healthcare. According to TipRanks, Mayo has an average return of 2.9% and a 49.75% success rate on recommended stocks. In addition to Leerink Partners, HCA Healthcare also received a Buy from Barclays's Andrew Mok CFA in a report issued on June 3. However, on May 29, Wells Fargo upgraded HCA Healthcare (NYSE: HCA) to a Hold. Based on HCA Healthcare's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $18.32 billion and a net profit of $1.61 billion. In comparison, last year the company earned a revenue of $17.34 billion and had a net profit of $1.59 billion Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year. Last month, Jon Foster, the EVP & COO of HCA sold 15,698.00 shares for a total of $5,797,585.36.
